TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18498993
Drug: Mitomycin-C (MMC)
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) 0.02% (0.2 mg/mL)
Study: 16256250
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (300 mg)
Study: 12655320
Drug: Ethanol 1.4
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethanol 1.4 g/kg
Study: 9113632
Drug: High-AA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-AA diet (1.7 g/d of arachidonic acid for 50 d)
Study: 3100859
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir (ACV)
Study: 18467303
Drug: Short-duration antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration antimicrobial treatment (5 days)
Study: 8649628
Drug: Microemulsion formulation
Normalized name: cyclosporine microemulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microemulsion formulation of cyclosporin A
Study: 28700781
Drug: High-dose spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spironolactone (100 mg)
Study: 28700781
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (placebo or 25 mg spironolactone)
Study: 10658445
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (no treatment)
Study: 22045829
Drug: tesaglitazar 2
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesaglitazar 2 mg
Study: 17166340
Drug: pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pioglitazone 45 mg
Study: 22045829
Drug: tesaglitazar 2
Normalized name: Tesaglitazar
DrugBank: Tesaglitazar (DB06536)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tesaglitazar 2 mg with ACE inhibitor
Study: 8150535
Drug: Radical cystectomy
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical cystectomy and pelvic-node dissection followed by adjuvant cisplatinum chemotherapy
Study: 25731690
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone (200 mg daily) until 34 weeks and 6 days' gestation
Study: 21945107
Drug: Whole-pelvis concurrent
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-pelvis concurrent chemoradiation (WP-CCRT)
Study: 21945107
Drug: Bladder-only concurrent
Normalized name: Sus scrofa urinary bladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bladder-only concurrent chemoradiation (BO-CCRT)
Study: 17469099
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 15 mg/week, increased every 3 months if Disease Activity Score >2.4, tapered after 12 months
Study: 2193629
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 mg/d
Study: 15262695
Drug: Thalidomide 100
Normalized name: thalidomide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 100 or 200 mg/d (after randomization)
Study: 15136218
Drug: Thalidomide treatment
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide treatment
Study: 17426158
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg)
Study: 12225503
Drug: Chloroquine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (40 mg/kg)
Study: 12225503
Drug: Sulfadoxine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfadoxine (500 mg) and Pyrimethamine (25 mg)
Study: 12225503
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg/kg)
Study: 9308538
Drug: implants not
Approvals — FDA: no, EMA: no, PMDA: no
Description: implants not removed
Study: 7213519
Drug: Spironolactone 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25, 50, 100 and 200 mg daily
Study: 29063827
Drug: Adalimumab injections
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab injections (80 mg and then 40 mg 2 weeks later) plus physiotherapy
Study: 25524507
Drug: Fluticasone furoate/vilanterol
Normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone furoate/vilanterol (FF/VI) 200/25 mcg
Study: 25524507
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 500 mcg
Study: 19289172
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg caffeine
Study: 21975110
Drug: Prolonged-release melatonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release melatonin (Circadin®) 2 mg daily
Study: 18669576
Drug: Budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 6 mg/day
Study: 11156722
Drug: Tirofiban (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (0.1 microg/kg/min intravenously) + Unfractionated heparin (intravenous, adjusted to activated partial thromboplastin time)
Study: 9660035
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 28 days prior to zolmitriptan administration
Study: 9660035
Drug: Zolmitriptan 10
Normalized name: zolmitriptan 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolmitriptan 10 mg oral dose
Study: 9660035
Drug: Zolmitriptan alone
Normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zolmitriptan alone or with fluoxetine
Study: 50126
Drug: Bleomycin via
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin via continuous infusion
Study: 31628043
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg twice daily plus best supportive care
Study: 23525448
Drug: PSI-697 600
Normalized name: psi-Norephedrine
DrugBank: Cathine (DB01486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSI-697 600 mg
Study: 23525448
Drug: P-selectin-blocking antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: P-selectin-blocking antibody (CLB-Thromb6)
Study: 10681341
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (1,920 mg over 3 days, four doses)
Study: 10681341
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (2,780 mg over 3 days, six doses)
Study: 10681341
Drug: Regimen C
Normalized name: ASPIRIN 81 mg ORAL TABLET, CHEWABLE [Bayer Aspirin Regimen Chewable Low Dose Aspirin Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen C (2,780 mg over 5 days, six doses)
Study: 10681341
Drug: Normal meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal meal close to drug administration
Study: 10681341
Drug: Higher-dose regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose regimens (B and C)
Study: 28774461
Drug: Bevacizumab (15mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (15mg/kg every 3 weeks) with carboplatin (AUC 5) and weekly paclitaxel (80mg/m2) for at least 6 cycles
Study: 25376448
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg QW for 12 weeks followed by 50 mg QW for 12 weeks
Study: 25376448
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg BIW/QW
Study: 22743849
Drug: Radiofrequency treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiofrequency treatment (RFT) of the soft palate
Study: 16873594
Drug: Face-to-face motivational
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face motivational interviewing plus telephone counseling and offering of medication
Study: 31344434
Drug: Patients whose
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients whose pain improved after palliative radiation therapy
Study: 31344434
Drug: Single fraction
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single fraction palliative radiation therapy (8 Gy) including reirradiation
Study: 31344434
Drug: Fractionated palliative
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated palliative radiation therapy (24 Gy in 6 fractions) including reirradiation
Study: 30104895
Drug: Ozone Injection
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozone Injection Group (OZG) - 6 mL of ozone 30 µg/mL injected into the center of the disc
Study: 27434505
Drug: Buprenorphine buccal
Normalized name: buprenorphine Buccal Film
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine buccal film (BBUP)
Study: 21034888
Drug: Peptide-based formula
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide-based formula with 3.5 g fructo-oligosaccharides and 3.8 g insoluble fiber/L
Study: 31909887
Drug: 5 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg/day isoniazid (INH)
Study: 31909887
Drug: 10 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg/day isoniazid (INH)
Study: 28461159
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (200,000 IU initial dose followed by 100,000 IU monthly)
Study: 26823746
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume of 7 ml/kg IBW with 8 cm H2O PEEP and recruitment
Study: 26823746
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume of 7 ml/kg IBW with 8 cm H2O PEEP
Study: 26823746
Drug: High volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High volume of 9 ml/kg IBW with ZEEP
Study: 17295604
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg/d)
Study: 17295604
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg/twice weekly)
Study: 15114301
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (Certoparin 3000 IU subcutaneously)
Study: 20646562
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia (PCEA) without low molecular heparin (LMWH)
Study: 20646562
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) without low molecular heparin (LMWH)
Study: 20646562
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) combined with low molecular heparin (LMWH)
Study: 18653492
Drug: Sugammadex (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2.0 mg kg(‐1)) administered at reappearance of the second twitch of the TOF.
Study: 10997756
Drug: Ventricular resynchronization
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventricular resynchronization therapy alone
Study: 10997756
Drug: Ventricular resynchronization
Normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventricular resynchronization therapy combined with cardioverter-defibrillator capability
Study: 10997756
Drug: Optimal pharmacological
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal pharmacological therapy alone
Study: 393076
Drug: Alcohol 0.8
Normalized name: isopropyl alcohol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.8 g/kg
Study: 3734141
Drug: Buspirone and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone and Diazepam pharmacokinetics
Study: 3734141
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of buspirone
Study: 29473354
Drug: Routine western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine western medicine with intravenous drip of ulinastatin (Control group).
Study: 26816234
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of Physta® standardized root water extract of Eurycoma longifolia (Tongkat Ali) for 4 weeks
Study: 18720881
Drug: Desloratadine and
Normalized name: Desloratadine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine and normal sodium spray
Study: 18720881
Drug: Desloratadine and
Normalized name: Desloratadine and pseudoephedrine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine and Nasonex spray
Study: 18720881
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and normal sodium spray
Study: 15820828
Drug: Vaginal bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal bromocriptine suppositories with Pluronic F127
Study: 15820828
Drug: Vaginal application
Normalized name: Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal application of bromocriptine tablets
Study: 24703170
Drug: Adjunctive medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive medroxyprogesterone acetate (MPA)
Study: 15983278
Drug: Housing contingent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing contingent on drug abstinence (ACH)
Study: 9467047
Drug: Granisetron (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron (10 micrograms/kg) administered as a 30-second intravenous bolus infusion
Study: 9467047
Drug: Ondansetron (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (32 mg) administered as a 15-minute intravenous infusion
Study: 8582214
Drug: Local arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local arterial infusion of 5-FU
Study: 9760009
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg)
Study: 4076202
Drug: Nicardipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (10 mg)
Study: 27136906
Drug: Losmapimod 20
Normalized name: Losmapimod
DrugBank: Losmapimod (DB12270)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod 20 mg
Study: 22610801
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol (1000 micrograms)
Study: 28292361
Drug: Intramuscular oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular oxytocin (10 units)
Study: 19702597
Drug: Bisoprolol 5
Normalized name: bisoprolol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 5 mg/day (n=9)
Study: 16153354
Drug: CMHN problem-solving
Normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMHN problem-solving treatment
Study: 7930304
Drug: Intranasal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal corticosteroids
Study: 1100179
Drug: Methotrexate treatment
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate treatment after craniospinal irradiation
Study: 24091311
Drug: HPV-16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 vaccine (Cervarix®; GlaxoSmithKline Vaccines)
Study: 15188794
Drug: Maintenance oral
Normalized name: Cystex Urinary Health Maintenance oral soluti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance oral nifedipine therapy (n=37) administered 20 mg every six hours
Study: 15188794
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (controls, n=36)
Study: 15188794
Drug: Maintenance oral
Normalized name: Cystex Urinary Health Maintenance oral soluti
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance oral nifedipine therapy (n=37)
Study: 27939836
Drug: Triptorelin 22.5
Normalized name: triptorelin 22.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 22.5 mg given as 24-week depot injections
Study: 31935529
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT), maximum 26 sessions, up to six months
Study: 30121618
Drug: Multisession cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisession cognitive-behavioural therapy (CBT)
Study: 30121618
Drug: One-session treatment
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session treatment (OST)
Study: 19887866
Drug: Capecitabine monotherapy
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine monotherapy (64% of patients, median starting dose 1,070 mg/m² b.i.d.)
Study: 14766712
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion at a starting rate of 6-9 microg kg(‐1) h(‐1) for up to 72 h, with additional propofol (0.5 mg kg(‐1) h(‐1) if required)
Study: 8183520
Drug: Systemic flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic flurbiprofen (added to topical drugs)
Study: 28200002
Drug: AbobotulinumtoxinA solution
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA solution for injection (ASI) 50 U
Study: 27765756
Drug: Nivolumab 10
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 10 mg/kg + gemcitabine/cisplatin (arm A)
Study: 25903058
Drug: Prompt group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt group (INT) received three daily screen-based prompts for 12 weeks.
Study: 12534402
Drug: onercept 11.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: onercept 11.7 mg three times weekly for 2 weeks
Study: 12534402
Drug: onercept 50
Normalized name: Onercept
DrugBank: Onercept (DB06495)
Approvals — FDA: no, EMA: no, PMDA: no
Description: onercept 50 mg three times weekly for 2 weeks
Study: 9275422
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg twice with 12 hours apart (Group 1)
Study: 9275422
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mifepristone 25 mg (Group 2)
Study: 9275422
Drug: Mifepristone 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 25 mg and anordrin 7.5 mg given once (Group 3)
Study: 17995496
Drug: E2/NETA (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2/NETA (1 mg 17beta estradiol plus 0.5 mg norethisterone acetate daily for 48 weeks)
Study: 17995496
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg daily for 48 weeks)
Study: 11498060
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (low ejection fraction subgroup)
Study: 3063047
Drug: Alinidine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alinidine (0.6 mg.kg‐1 i.v.)
Study: 3063047
Drug: Metoprolol (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.035 mg.kg‐1 i.v.)
Study: 19393840
Drug: Extended-release quetiapine
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release quetiapine fumarate (XR)
Study: 19393840
Drug: Immediate-release quetiapine
Normalized name: quetiapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release quetiapine fumarate (IR)
Study: 7883933
Drug: Intramuscular sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular sedation (meperidine and promethazine)
Study: 2204333
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of papaveretum (n = 8)
Study: 28381198
Drug: Clopidogrel combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel combined with aspirin
Study: 12787540
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin and aspirin
Study: 9403227
Drug: Tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 200 mg
Study: 25050456
Drug: Ciprofloxacin DPI
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin DPI 65 mg
Study: 17560446
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (12-h intervals)
Study: 17560446
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (3-h intervals)
Study: 11426001
Drug: 2 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mmol/L gadoteridol
Study: 11426001
Drug: 4 mmol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mmol/L gadoteridol
Study: 8008413
Drug: Phentolamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (30 mg) administered intravenously
Study: 1987713
Drug: Nifedipine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (80 mg/day, 4 times per day)
Study: 25486290
Drug: Nifedipine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (80 mg/day)
Study: 27884418
Drug: 700 cGy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 700 cGy dose of radiation
Study: 26919705
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with chin bone
Study: 26919705
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with chin bone plus a membrane
Study: 10575270
Drug: BCG immunotherapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG immunotherapy (standard regimen)
Study: 30033196
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping (KT) applied every 3 days for children with up to three incontinence episodes per day, and daily for those with more frequent episodes